Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US1101221083
Ticker BMY
Company BRISTOL-MYERS SQUIBB
Currency $
Price
Aware Investor Index (AII) 3.3271
Recommendation BUY
P/E 33.02
ROE 22.20 %
Capitalization 86,862,160,000 $
Dividend Yield 2.99 %
P/S 4.18
AII Position 166
P/E Position 491
ROE Position 133
Capitalization Position 91
Dividend Yield Position 247
Sales 20,776,000,000 $
10-Year Average Earnings 2,630,300,000 $
Shares Outstanding 1,652,000,000
Equity 11,847,000,000 $
Dividend per Share 1.57 $
Industry Pharmaceutical
Country United States
BRISTOL-MYERS SQUIBB Investor Relations Web Site https://www.bms.com/investors.html







Sales:

YEAR MONTH AMOUNT
2017 12 20,776,000,000.00 $
2016 12 19,427,000,000.00 $
2015 12 16,560,000,000.00 $
2014 12 15,879,000,000.00 $
2013 12 16,385,000,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 1,007,000,000.00 $
2016 12 4,457,000,000.00 $
2015 12 1,565,000,000.00 $
2014 12 2,004,000,000.00 $
2013 12 2,563,000,000.00 $
2012 12 1,960,000,000.00 $
2011 12 3,709,000,000.00 $
2010 12 3,102,000,000.00 $
2009 12 3,239,000,000.00 $
2008 12 2,697,000,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 11,847,000,000.00 $
2016 12 16,347,000,000.00 $
2015 12 14,424,000,000.00 $
2014 12 14,983,000,000.00 $
2013 12 15,236,000,000.00 $
2012 12 13,638,000,000.00 $
2011 12 15,867,000,000.00 $
2010 12 15,638,000,000.00 $
2009 12 14,785,000,000.00 $
2008 12 12,208,000,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 1,652,000,000
2016 12 1,680,000,000
2015 12 1,679,000,000
2014 12 1,670,000,000
2013 12 1,662,000,000
2012 12 1,688,000,000
2011 12 1,717,000,000
2010 12 1,727,000,000
2009 12 1,978,000,000
2008 12 1,999,000,000

 












Bloomberg News for BRISTOL-MYERS SQUIBB:



Google News for BRISTOL-MYERS SQUIBB:

Seeking Alpha - 12 hours ago
Bristol-Myers Squibb Stock Issued For Celgene: I Plan To Keep It
Bristol-Myers Squibb (BMY) is buying Celgene (CELG), with the deal likely to close in Q3. I do not own BMY stock, though I have looked at that ...
StreetInsider.com
Bristol-Myers Squibb (BMY) Announces European Commission ...
Bristol-Myers Squibb (BMY) Announces European Commission Approval for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab).
KYMA News
Congressmen urge DOJ to scrutinize Bristol-Myers Squibb ...
Congressmen urge DOJ to scrutinize Bristol-Myers Squibb - Celgene ... a "careful examination" of Bristol-Myers Squibb's (BMY +0.7%) $74B ...
Equities.com
Bristol-Myers Squibb And Celgene
So our big biopharma news this morning is Bristol-Myers Squibb (NYSE:BMY) buying Celgene (NASDAQ:CELG), for $74 billion. I don't think ...
StreetInsider.com - 1 day ago
Instant Alterations: – Bristol-Myers Squibb Company, (NYSE: BMY)
On 14-01-2019 (Monday), the Healthcare stock (Bristol-Myers Squibb Company) created a change of -0.04 percent (Loss, ↓) and closed its ...
Seeking Alpha - 1 day ago
Bristol-Myers Squibb (BMY) Reports Offer from Taisho ...
Bristol-Myers Squibb Company (NYSE: BMY) today announced that Taisho Pharmaceutical Holdings Co., Ltd. (Taisho) has offered to purchase ...
Seeking Alpha - 3 Jan 2019
Bristol-Myers Squibb (BMY) call put ratio 2.5 calls to 1 put with focus ...
Bristol-Myers Squibb (NYSE: BMY) call put ratio 2.5 calls to 1 put with focus on February 50 and March 55 calls.
Bloomberg
Eli Lilly, Loxo Make More Sense Than Bristol Myers, Celgene
Last week, Bristol Myers Squibb (BMY) went public with its acquisition of Celgene (CELG) and this week Eli Lilly (LLY) announced its own ...
StreetInsider.com
Why Is Celgene A Strategic Fit For Bristol-Myers Squibb
Bristol-Myers Squibb (NYSE:BMY) recently announced its plan to merge with Celgene in a $74 billion deal. The combined entity will have ...
CNBC
What Should Celgene Shareholders Do In Light Of The Bristol ...
The stock appreciated about 21% as of writing, as there was news that Bristol-Myers Squibb (BMY) was acquiring Celgene for about $74 billion ...


Back